cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of Sintilimab plus Transcatheter arterial
chemoembolization (TACE) in participants with Intermediate-stage unresectable hepatocellular
carcinoma with Beyond Up-to-seven Criteria.